Introduction
============

Radiation therapy (RT) has long been the mainstay treatment for the patients with non-metastatic nasopharynx cancer (NPC), which can lead to 62%-80% of 5-year overall survival (OS) rate \[[@b1-crt-2018-240]\]. Considering relatively younger median age of NPC patients (45-50 years) than other head and neck cancers \[[@b2-crt-2018-240]\], higher level of attention needs to be paid to the quality of life following RT. Xerostomia, altered taste, and dysphagia with mucositis are the most common acute adverse effects during and following RT, which not only bother the patients with pain, but also often interrupt the planned RT course. Chronic xerostomia and altered taste often restrict the patients' capability of speech and swallowing, which often limit their social interactions.

NPC is associated with lymph node (LN) metastasis frequently (60%-90%) at time of diagnosis \[[@b3-crt-2018-240]\]. LN metastasis is usually predictable by virtue of orderly spread pattern and skip metastasis is rare. Nevertheless, bilateral entire neck irradiation used to be typically recommended in RT for NPC patients. This was based on the classic reports on lymphatic failure rates following no elective nodal irradiation (ENI) (40%) and partial neck irradiation (12%) in most non-NPC head and neck cancer patients \[[@b4-crt-2018-240],[@b5-crt-2018-240]\]. In the earlier days, when the quality of diagnostic imaging was not satisfactory, discrimination between metastatic and normal LNs was not an easy task. Furthermore, reduced ENI volume did not make big difference in normal organ sparing over entire neck irradiation when the advanced RT techniques such as 3-dimensional conformal RT (3DCRT) and intensity modulated RT (IMRT) were not available. Instead, reduced ENI volume was not widely accepted in fear of missing probable metastatic LNs. However, the refinement of diagnostic imaging modalities and the technical advances in RT have enabled the delivery of selective neck irradiation (SNI) and consequent saving of more surrounding normal organs from high dose radiation. Based on these, tailored lymphatic target volume delineation has recently become popular.

Our institution has employed the SNI policy with lower radiation dose in treating the NPC patients for longer than two decades, and the current study is to report our experiences of the clinical outcomes and toxicities.

Materials and Methods
=====================

1. Patients
-----------

After approval by the institutional review board, 347 patients who received definitive RT for newly diagnosed non-metastatic NPC from January 2001 to December 2015 were retrospectively reviewed. All patients underwent thorough physical examination, histopathologic confirmation, and computed tomography (CT) scan of the head and neck region. Magnetic resonance imaging was done in 108 patients (31.1%), in whom the skull base and/or intracranial invasion was suspected. Systemic staging work-up's during the early study period included whole body bone scintigraphy and abdominal ultrasonography in 54 patients (15.6%), which were later replaced by whole-body 5-fluorodeoxyglucose positron emission tomography and computed tomography (FDG PET-CT) in 293 (84.4%). Clinical T-stage (cT) and clinical N-stage (cN) categories were allocated according to the seventh edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual \[[@b6-crt-2018-240]\].

2. Target volume delineation
----------------------------

All the patients underwent CT simulation. The delineation of the gross tumor volume (GTV) of the primary tumor and LN was done with reference to all the clinically available information including physical examination and imaging studies. The diagnosis of metastatic LNs was based either on cyto-histologic confirmation or on more than one of the following radiologic criteria: short axis ≥ 1 cm (cervical LN) or ≥ 6 mm (retropharyngeal LN); findings of contrast enhancement, round shape, central nodal necrosis, and/or irregular margin with infiltration to the surrounding structure; and evident FDG uptake regardless of the LN size \[[@b7-crt-2018-240],[@b8-crt-2018-240]\]. The clinical target volume (CTV) of the primary tumor was delineated by adding 3-5 mm margins in all directions from GTV of the primary tumor and included the sphenoid sinus, posterior part of nasal cavity and maxillary sinus, and skull base in case of skull base invasion. The lymphatic CTVs were divided into two components: CTV at high risk (CTV-HR) was to encompass the immediately adjacent lymphatic levels to the nodal GTV with 1.0-1.5 cm margins; and CTV at low risk (CTV-LR) was to include addition 2.0-2.5 cm distal lymphatics from CTV-HR ([Fig. 1](#f1-crt-2018-240){ref-type="fig"}). All CTVs were edited considering the normal anatomic barriers of the surrounding structures. The planning target volume was generated by adding 3 mm margin to CTV.

3. Treatment
------------

The majority of patients (n=289, 83.3%) were treated by RT combined with chemotherapy, while RT alone was delivered to 58 patients (16.7%), who either had cT1-2N0 disease or medical comorbidities contraindicating chemotherapy ([Table 1](#t1-crt-2018-240){ref-type="table"}). Concurrent chemoradiation therapy alone was delivered to 188 patients (54.2%). Neoadjuvant and adjuvant chemotherapy before or following RT were delivered to 12 (3.5%) and 90 patients (25.9%), respectively, both of which were given mainly during the early study period.

4. RT techniques and schedules
------------------------------

During the early part of the current study, 3DCRT was the main technique applied to 152 patients (43.8%). By serial shrinking and adaptive re-plans, twice during the course, the typical doses delivered to GTV, CTV-HR, and CTV-LR were 70.0 Gy, 54.0 Gy, and 36.0 Gy over 7 weeks by daily 1.8 Gy or 2.0 Gy per fraction, respectively. During the later part, when the Korean Health Insurance Policy began to cover the IMRT cost, IMRT by helical tomotherapy was mainly used to treat 195 patients (56.2%). The simultaneous integrated boost and adaptive re-plan were employed when using IMRT, and the typical doses to GTV, CTV-HR, and CTV-LR were 68.4 Gy, 60.0 Gy, and 36.0 Gy over 6 weeks, respectively. The typical fractional dose to GTV and CTV were 2.2 Gy and 2.0 Gy during the first 18 fractions and 2.4 Gy and 2.0 Gy during the remaining 12 fractions.

5. Follow-up evaluation and statistical analysis
------------------------------------------------

The first clinical evaluation was done with CT scan taken in 1 month of RT completion, and the second evaluation was done with PET-CT in 3 months of the first evaluation. The subsequent follow-up evaluations were scheduled at every 3-4 months' interval during the first 2 years, at every 6 months' interval during the third year, and then annually thereafter. Loco-regional failure was defined as the reappearance or new lesion development at the primary site and/or regional lymphatics. The durations of loco-regional control (LRC), progression-free survival (PFS), and OS were calculated from the date of RT start till the date of the event or the last follow-up. The rates of LRC, PFS, and OS were calculated using the Kaplan-Meier methods. All the analyses were conducted using the SPSS Statistics ver. 20 (IBM Corp., Armonk, NY).

6. Ethical statement
--------------------

The study was approved by the Institutional Review Board of Samsung Medical Center (IRB No. 2011-11-105-002) and performed in accordance with the principles of the Declaration of Helsinki. The informed consent was waived.

Results
=======

1. Patients' characteristics
----------------------------

The patients' characteristics are summarized in [Table 1](#t1-crt-2018-240){ref-type="table"}. The median age of all patients was 51 years (range, 16 to 86 years), and 267 patients (76.9%) were male. The most common histologic type was undifferentiated carcinoma in 197 patients (59.9%), followed by non-keratinizing carcinoma, differentiated type in 67 (20.4%), keratinizing squamous cell carcinoma in 56 (17.0%), and unclassified in nine (2.7%), respectively. cT categories were cT1 in 157 patients (45.2%), cT2 in 45 (13.0%), cT3 in 80 (23.1%), and cT4 in 65 (18.7%), respectively. cN categories were cN0 in 50 patients (14.4%), cN1 in 97 (28.0%), cN2 in 148 (42.7%), and cN3 in 52 (15.0%), respectively.

2. Clinical outcomes and patterns of first failure
--------------------------------------------------

The median follow-up duration was 68.1 months (range, 2.3 to 197.1 months), during which 100 patients (28.8%) developed disease progression and 83 (23.9%) died, respectively. The 5-year rates of LRC, PFS, and OS were 85.0%, 70.8%, and 81.1%, respectively. Distant metastasis was the most common component observed in 59 patients (17.1%), followed by components of regional and local failures in 30 (8.7%) and 28 (8.1%), respectively ([Fig. 2](#f2-crt-2018-240){ref-type="fig"}). The most common site of distant metastasis was the lung observed in 23 patients, followed by the bone in 13, and the liver in six, respectively.

3. Location of regional failure and salvage treatment
-----------------------------------------------------

The sites of regional failure in 30 patients were classified in relation to the target volumes: failure exclusively within CTV-HR in 20 (5.7%); failure synchronously inside and outside CTV-HR in three (0.9%); and failure exclusively outside CTV-HR in seven (2.0%), respectively ([Fig. 3](#f3-crt-2018-240){ref-type="fig"}). Among seven patients who developed exclusively outside CTV-HR failure, four (1.1%) developed exclusively inside CTV-LR failure, one (0.3%) did synchronous inside and outside CTV-LR failure, and two (0.6%) did exclusively outside CTV-LR failure, respectively. Salvage treatment was attempted in four patients, all of whom were successfully salvaged, while three (no treatment in two and palliative systemic chemotherapy in one) died of disease. The 5-year regional control rates of the patients with cN0, cN1, cN2, and cN3 disease were 94.0%, 85.3%, 94.2%, and 95.6%, respectively.

4. Toxicities
-------------

[Table 2](#t2-crt-2018-240){ref-type="table"} summarizes RT-related toxicity profiles. Grade 3 or higher acute toxicities developed in 44 patients (12.7%) and mucositis (n=19, 5.5%) and nausea/vomiting (n=19, 5.5%) were most frequent followed by dermatitis (n=4, 1.2%) and neutropenia (n=2, 0.6%). Grade 3 or higher chronic toxicities included cranial neuropathy in 11 patients (3.2%), mucosal necrosis in four (1.2%), and brain necrosis in three (0.9%), respectively. Grade 2 or higher xerostomia persisting longer than 3, 12, and 24 months following RT completion was observed in 38 (11.0%), 23 (6.6%), and 15 patients (4.3%), respectively.

Discussion
==========

Most previous clinical trials regarding NPC treatment advocated the routine bilateral entire neck irradiation from the retropharyngeal LNs to the level IV/V \[[@b9-crt-2018-240]\]. However, the rarity of skip metastasis in NPC and the improved LN assessment by advanced diagnostic imaging, coupled with the increased concern on post-RT quality of life, have promoted to the introduction of SNI. The feasibility of omitting level Ib or IV/Vb from the lymphatic target volume is most frequently addressed in regards to SNI. One analysis on 1,438 NPC patients examined the safety of level Ib-sparing IMRT \[[@b10-crt-2018-240]\], and reported only three recurrences at level Ib (0.2%). Chen et al. \[[@b11-crt-2018-240]\] evaluated the impact of omitting levels IV/Vb in 212 cN0-1 NPC patients and affirmed the effectiveness and safety of the SNI strategy. Gao et al. \[[@b12-crt-2018-240]\] also employed SNI limited to level II, III, and Va in treating 410 cN0 NPC patients, and observed only one relapse (0.2%) outside this volume. On the basis of aforementioned evidence, the most up-to-date international guideline does not recommend the routine inclusion of ipsilateral level Ib and IV/Vb to nodal CTV \[[@b13-crt-2018-240]\].

The current guidelines regarding the ENI volume delineation are based on the anatomic landmarks which include the hyoid bone, cricoid cartilage, posterior margin of the sternocleidomastoid muscle, and the line between shoulder and neck junction to medial clavicle end \[[@b13-crt-2018-240]\]. These anatomic landmarks are proposed mainly for surgeons' as they are easily identifiable to provide information during surgery, however, are less meaningful to radiation oncologists, as they are not relevant to the cancer cells' spread through the lymphatic channels. Instead of the surgical landmark-based LN levels, the current study employed lymphatic CTV delineation policy by adding differential margins from GTV of LN.

The ENI dose of 44-64 Gy to the clinically uninvolved lymphatics has usually been recommended in most head and neck cancer types \[[@b13-crt-2018-240]\]. However, there has been no clear guidance on the optimal ENI dose in treating the NPC patients. Fletcher \[[@b5-crt-2018-240]\] reported that 50 Gy could eradicate 95% of subclinical disease, whereas 30-40 Gy were associated with regional relapse in 9%-10.5%. These recommendations were based on the data collected during the first generation CT era, when the image quality was suboptimal in detecting subclinical disease compared with the current standard. The tumor control probability (TCP) is, theoretically as well as practically, associated with the tumor burden and likelihood of occult disease, and so is the elective radiation dose to achieve effective tumor control \[[@b14-crt-2018-240],[@b15-crt-2018-240]\]. Assuming that the probability of occult disease be 20%, the radiation dose in order to achieve TCP of 95% would be 40-50 Gy, if the occult disease tumor burden is equivalent to 10 mm sized gross tumor, and would become 35-40 Gy if the tumor burden is equivalent to 5-mm-sized gross tumor \[[@b16-crt-2018-240]\]. With the advances in diagnostic imaging modalities, detection of metastatic deposits in the LNs has become much easier than in the past, and the elective radiation dose also needs to be redefined accordingly. van den Bosch et al. \[[@b16-crt-2018-240]\] also suggested that elective dose of 36 Gy might be feasible theoretically with the current diagnostic strategies to achieve 95% of TCP. Moreover, favorable clinical outcomes were achievable following elective dose of 36 Gy in treating human papillomavirus (HPV)--related anal cancer \[[@b17-crt-2018-240]\], and there are emerging evidences supporting to deliver 36 Gy as elective dose in treating HPV-associated oropharyngeal cancer. These imply the feasibility of 36 Gy in treating nasopharyngeal cancer that is usually associated with Epstein-Barr virus infection.

In addition, there were several clinical studies that addressed the feasibility of lower ENI dose in treating head and neck cancer \[[@b18-crt-2018-240],[@b19-crt-2018-240]\]. Bedi et al. \[[@b18-crt-2018-240]\] showed no difference in LRC in the patients who received lower than conventional ENI dose. Salama et al. \[[@b19-crt-2018-240]\] compared three different ENI dose schemes (45 Gy, 39 Gy, and 36 Gy) in treating the head and neck cancer patients, and found that LRC and OS were not different among the groups. A prospective trial \[[@b20-crt-2018-240]\], which compared elective doses of 40 Gy and 50 Gy, demonstrated that lower ENI dose was not inferior with respects to LRC and OS. In the current study, seven among 30 patients (23.3%) who developed regional recurrence had exclusively outside GTV/CTV-HR recurrence. Kong et al. \[[@b21-crt-2018-240]\] reported that, following bilateral whole neck irradiation except level IB with 54 Gy, three of 11 patients (27.3%) developed regional recurrence within the elective irradiation volume. Although fair comparison is impossible because of heterogeneity in tumor characteristics and RT dose schedules, the recurrence rates in the elective volume in the current study do not seem detrimental. Not only LRC and OS but also regional control rate of the current study (92.6% at 3 years) was not inferior, when compared to the previous studies that employed entire neck irradiation policy ([Table 2](#t2-crt-2018-240){ref-type="table"}).

One may raise an argument in that one should not take the risk of recurrence by reducing ENI volume and dose, as the RT toxicities may not be severe if IMRT is used. However, a recent study regarding the oral health quality of the head and neck cancer patients following IMRT reported that the salivary flow was recovered only by 40% and suggested that further reduced dose to the salivary glands is warranted \[[@b26-crt-2018-240]\]. Several retrospective studies revealed that reduced mean dose to the submandibular gland, oral cavity, and parotid gland is associated with diminished patient-reported xerostomia without increasing local recurrences \[[@b27-crt-2018-240],[@b28-crt-2018-240]\]. Along with the advances in RT technique, lower elective dose can attribute to reduce toxicities by decreasing the irradiated dose of normal organs \[[@b16-crt-2018-240]\]. Two prospective studies reported lower ENI dose could prevent dysphagia and salivary dysfunction \[[@b20-crt-2018-240],[@b29-crt-2018-240]\]. A recent phase II study also revealed that the lower elective dose of 36 Gy in head and neck cancer patients improved the patient-reported quality of life score and decreased the rate of percutaneous feeding gastrostomy tube insertion \[[@b30-crt-2018-240]\].

Despite the retrospective nature, the current study is the first one reporting the clinical outcomes following reduced ENI volume and lower ENI dose of 36 Gy in treating the NPC patients. The clinical outcomes of the current study could support the feasibility of authors' policy of SNI with lower elective dose in treating nasopharyngeal cancer. Thorough image evaluation and meticulous peer review in target delineation process are deemed integral points for the successful execution of the SNI policy. Larger prospective clinical trials, however, might be warranted to endorse our conclusions.
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![The policy of selective neck irradiation with differential radiation dose plan employed in the current study is illustrated: (A) 66-72 Gy to gross tumor volume (GTV) of primary tumor and metastatic lymph nodes; (B) 54-60 Gy to clinical target volume at high risk (CTV-HR) that included 1.0-1.5 cm margin to nodal GTV; and (C) 36 Gy to clinical target volume at low risk (CTV-LR) that included 2-2.5 cm distal margin from CTV-HR.](crt-2018-240f1){#f1-crt-2018-240}

![Patterns of failure in 100 patients.](crt-2018-240f2){#f2-crt-2018-240}

![The sites of regional failures in relation to target volume and detail of seven patients who developed regional failure in or outside clinical target volume at low risk (CTV-LR). GTV, gross tumor volume; CTV-HR, clinical target volume at high risk. RT, radiotherapy; NED, no evidence of disease; DOD, dead of disease; M, male.](crt-2018-240f3){#f3-crt-2018-240}

###### 

Patients' characteristics

  Characteristic                                     No. (%) (n=347)
  -------------------------------------------------- -----------------
  **Age, median (range, yr)**                        51 (16-86)
  **Sex**                                            
   Male                                              267 (76.9)
   Female                                            80 (23.1)
  **Performance status**                             
   ECOG 0-1                                          336 (96.8)
   ECOG 2                                            11 (3.2)
  **Histologic type**                                
   Keratinizing squamous cell carcinoma              56 (17.0)
   Non-keratinizing carcinoma, differentiated type   67 (20.4)
   Undifferentiated carcinoma                        197 (59.9)
   Unclassified                                      9 (2.7)
  **Imaging studies**                                
   CT                                                3 (0.9)
   CT, MRI                                           51 (14.7)
   CT, FDG-PET                                       236 (68.0)
   CT, MRI, FDG-PET                                  57 (16.4)
  **Clinical T category**                            
   cT1                                               157 (45.2)
   cT2                                               45 (13.0)
   cT3                                               80 (23.1)
   cT4                                               65 (18.7)
  **Clinical N category**                            
   cN0                                               50 (14.4)
   cN1                                               97 (28.0)
   cN2                                               148 (42.7)
   cN3                                               52 (15.0)
  **Treatment**                                      
   RT alone                                          58 (16.7)
   NAC+RT                                            1 (0.3)
   CCRT alone                                        188 (54.2)
   NAC+CCRT                                          10 (2.9)
   CCRT+AC                                           89 (25.6)
   NAC+CCRT+AC                                       1 (0.3)
  **RT technique**                                   
   3D-CRT                                            152 (43.8)
   IMRT                                              195 (56.2)

ECOG, Eastern Cooperative Oncology Group; CT, computed tomography; MRI, magnetic resonance imaging; FDG, 5-fluorodeoxyglucose; PET, positron emission tomography; RT, radiation therapy; NAC, neoadjuvant chemotherapy; CCRT, concurrent chemoradiotherapy; AC, adjuvant chemotherapy; 3D-CRT, 3 dimensional conformal RT; IMRT, intensity-modulated RT.

###### 

Comparison of regional control rates and survival between the current study and other studies employing entire neck irradiation

  Study                                          No. of patients   Median FU (mo)   Regional control rate   Survival outcomes (%)
  ---------------------------------------------- ----------------- ---------------- ----------------------- -----------------------
  Wolden et al. (2006) \[[@b22-crt-2018-240]\]   74                35               93% at 3 yr             OS 83 at 3 yr
                                                                                                            DFS 67 at 3 yr
  Wong et al. (2010) \[[@b23-crt-2018-240]\]     175               34               93.3% at 3 yr           OS 87.2 at 3 yr
                                                                                                            DMFS 86.6 at 3 yr
  Wang et al. (2013) \[[@b24-crt-2018-240]\]     300               80.2             95.1% at 4 yr           OS 96.1 at 4 yr
                                                                                                            DMFS 87.4 at 4 yr
  Au et al. (2018) \[[@b25-crt-2018-240]\]       3,328             80.2             91.5% at 8 yr           OS 68.5 at 8 yr
                                                                                                            DFS 62.6 at 8 yr
  Current study                                  347               68.1             92.6% at 3 yr           OS 87.1 at 3 yr
                                                                                                            DFS 74.7 at 3 yr

FU, follow-up; OS, overall survival; DFS, disease-free survival; DMFS, distant metastasis-free survival.
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